Clinical trial · Observational
COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer
COVID 19 Pandemic: Effect on Management of Patients With Breast Cancer; Single Center Study
NCT04929964CI-TRIAL-00053211COVID-19completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective was to find out the impact of COVID-19 on stage of breast cancer at presentation and its effects on overall onco-surgical management. The investigator carried out this research to see the presenting stage of breast cancer in the participants in this pandemic and correlate its effect on stage of breast cancer and upstaging of disease
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Stage | — | UNRESOLVED | — |
| Covid19 | — | UNRESOLVED | — |
| Isolation, Social | — | UNRESOLVED | — |
| Locally Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRM , Toilet Mastectomy , BCS | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Breast cancer
- interventionNames
- Procedure: MRM , Toilet Mastectomy , BCS
Primary outcomes (3)
- measure
- Duration of delay in presentation to hospital
- timeFrame
- 18 months
- description
- It was time counted from the day when the participant first felt breast symptom on self assessment or during diagnostic workup and than presented for the first time to hospital for diagnostic or treatment workup purpose
- measure
- Duration of delay in definitive treatment
- timeFrame
- 18 months
- description
- It was counted from the day of first presentation to hospital till the day of initiation of definitive treatment (chemo/surgery)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 71 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of breast cancer confirmed on histo-pathological examination Exclusion Criteria: * Patients who had already had their surgery pre covid (December 2019)
References
Publications (4)
- BACKGROUNDGulzar F, Akhtar MS, Sadiq R, Bashir S, Jamil S, Baig SM. Identifying the reasons for delayed presentation of Pakistani breast cancer patients at a tertiary care hospital. Cancer Manag Res. 2019 Jan 29;11:1087-1096. doi: 10.2147/CMAR.S180388. eCollection 2019. PMID 30774437
- BACKGROUNDKhan MA, Shafique S, Khan MT, Shahzad MF, Iqbal S. Presentation delay in breast cancer patients, identifying the barriers in North Pakistan. Asian Pac J Cancer Prev. 2015;16(1):377-80. doi: 10.7314/apjcp.2015.16.1.377. PMID 25640384
- BACKGROUNDVuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A, Bellesoeur A, Servois V, Hequet D, Laas E, Kirova Y, Cabel L, Pierga JY; Institut Curie Breast Cancer and COVID Group; Bozec L, Paoletti X, Cottu P, Bidard FC. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Res. 2020 May 28;22(1):55. doi: 10.1186/s13058-020-01293-8. PMID 32460829
- RESULTElghazawy H, Bakkach J, Zaghloul MS, Abusanad A, Hussein MM, Alorabi M, Eldin NB, Helal T, Zaghloul TM, Venkatesulu BP, Elghazaly H, Al-Sukhun S. Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic. Future Oncol. 2020 Nov;16(31):2551-2567. doi: 10.2217/fon-2020-0574. Epub 2020 Jul 27. PMID 32715776